Core Viewpoint - OXB has shown strong commercial momentum and operational progress in 2025, continuing to provide viral vector manufacturing services to a diverse client base, and remains on track to meet its financial outlook for the year ended December 31, 2024 [2][3]. Group 1: Company Performance - OXB has delivered strong operational performance in the first half of 2025, reflecting disciplined execution across global sites and sustained commercial momentum [3]. - The company reiterates its financial guidance and remains focused on supporting clients at all development stages, expressing confidence in its near and medium-term targets [3]. Group 2: Company Background - OXB is a pioneer in cell and gene therapy with 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies [5]. - The company provides expertise in various viral vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus, supporting capabilities from early-stage development to commercialization [5]. Group 3: Technological Capabilities - OXB offers unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6]. - The company utilizes advanced processes such as suspension and perfusion with process enhancers, along with stable producer and packaging cell lines [6]. Group 4: Corporate Information - OXB is headquartered in Oxford, UK, with development and manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford, MA, US [7].